Ability of procalcitonin to distinguish between bacterial and nonbacterial infection in severe acute exacerbation of chronic obstructive pulmonary syndrome in the ICU.
Antibiotic stewardship
Chronic obstructive pulmonary disease
Community-acquired pneumonia
Procalcitonin
Respiratory tract infection
Viral infection
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
06 Mar 2021
06 Mar 2021
Historique:
received:
26
10
2020
accepted:
27
01
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
7
3
2021
Statut:
epublish
Résumé
To assess the ability of procalcitonin (PCT) to distinguish between bacterial and nonbacterial causes of patients with severe acute exacerbation of COPD (AECOPD) admitted to the ICU, we conducted a retrospective analysis of two prospective studies including 375 patients with severe AECOPD with suspected lower respiratory tract infections. PCT levels were sequentially assessed at the time of inclusion, 6 h after and at day 1, using a sensitive immunoassay. The patients were classified according to the presence of a documented bacterial infection (including bacterial and viral coinfection) (BAC + group), or the absence of a documented bacterial infection (i.e., a documented viral infection alone or absence of a documented pathogen) (BAC- group). The accuracy of PCT levels in predicting bacterial infection (BAC + group) vs no bacterial infection (BAC- group) at different time points was evaluated by receiver operating characteristic (ROC) analysis. Regarding the entire cohort (n = 375), at any time, the PCT levels significantly differed between groups (Kruskal-Wallis test, p < 0.001). A pairwise comparison showed that PCT levels were significantly higher in patients with bacterial infection (n = 94) than in patients without documented pathogens (n = 218) (p < 0.001). No significant difference was observed between patients with bacterial and viral infection (n = 63). For example, the median PCT-H Despite higher PCT levels in severe AECOPD caused by bacterial infection, PCT had a poor accuracy to distinguish between bacterial and nonbacterial infection. Procalcitonin might not be sufficient as a standalone marker for initiating antibiotic treatment in this setting.
Sections du résumé
BACKGROUND
BACKGROUND
To assess the ability of procalcitonin (PCT) to distinguish between bacterial and nonbacterial causes of patients with severe acute exacerbation of COPD (AECOPD) admitted to the ICU, we conducted a retrospective analysis of two prospective studies including 375 patients with severe AECOPD with suspected lower respiratory tract infections. PCT levels were sequentially assessed at the time of inclusion, 6 h after and at day 1, using a sensitive immunoassay. The patients were classified according to the presence of a documented bacterial infection (including bacterial and viral coinfection) (BAC + group), or the absence of a documented bacterial infection (i.e., a documented viral infection alone or absence of a documented pathogen) (BAC- group). The accuracy of PCT levels in predicting bacterial infection (BAC + group) vs no bacterial infection (BAC- group) at different time points was evaluated by receiver operating characteristic (ROC) analysis.
RESULTS
RESULTS
Regarding the entire cohort (n = 375), at any time, the PCT levels significantly differed between groups (Kruskal-Wallis test, p < 0.001). A pairwise comparison showed that PCT levels were significantly higher in patients with bacterial infection (n = 94) than in patients without documented pathogens (n = 218) (p < 0.001). No significant difference was observed between patients with bacterial and viral infection (n = 63). For example, the median PCT-H
CONCLUSION
CONCLUSIONS
Despite higher PCT levels in severe AECOPD caused by bacterial infection, PCT had a poor accuracy to distinguish between bacterial and nonbacterial infection. Procalcitonin might not be sufficient as a standalone marker for initiating antibiotic treatment in this setting.
Identifiants
pubmed: 33675432
doi: 10.1186/s13613-021-00816-6
pii: 10.1186/s13613-021-00816-6
pmc: PMC7936235
doi:
Types de publication
Journal Article
Langues
eng
Pagination
39Références
Lancet Infect Dis. 2018 Jan;18(1):95-107
pubmed: 29037960
Am J Respir Crit Care Med. 2006 Jul 1;174(1):84-93
pubmed: 16603606
Int J Environ Res Public Health. 2020 Nov 02;17(21):
pubmed: 33147795
Braz J Med Biol Res. 2018;51(7):e6783
pubmed: 29846409
BMC Infect Dis. 2009 Sep 21;9:157
pubmed: 19772586
Cochrane Database Syst Rev. 2012 Dec 12;12:CD010257
pubmed: 23235687
Intensive Care Med. 2018 Jul;44(7):1061-1070
pubmed: 29959455
Lancet. 2010 Feb 6;375(9713):463-74
pubmed: 20097417
Am J Respir Crit Care Med. 2008 Mar 1;177(5):498-505
pubmed: 18096708
Clin Microbiol Infect. 2015 May;21(5):474-81
pubmed: 25726038
Crit Care. 2009;13(3):R83
pubmed: 19493352
Intensive Care Med. 2018 Apr;44(4):428-437
pubmed: 29663044
Lancet. 2004 Feb 21;363(9409):600-7
pubmed: 14987884
BMC Infect Dis. 2008 Oct 23;8:145
pubmed: 18947382
Lancet Infect Dis. 2016 Jul;16(7):819-827
pubmed: 26947523
Clin Microbiol Infect. 2009 May;15(5):481-7
pubmed: 19416298
Medicine (Baltimore). 2019 Aug;98(32):e16775
pubmed: 31393400
Lancet Infect Dis. 2013 May;13(5):426-35
pubmed: 23375419
Eur Respir J. 2009 Dec;34(6):1364-75
pubmed: 19797133
Crit Care Med. 2012 Aug;40(8):2304-9
pubmed: 22809906
Int J Chron Obstruct Pulmon Dis. 2016 Jun 22;11:1381-9
pubmed: 27382274
Infect Dis (Lond). 2019 Sep;51(9):639-650
pubmed: 31355690
Am J Respir Crit Care Med. 2019 Jun 15;199(12):1496-1507
pubmed: 30562053
Respirology. 2011 Jul;16(5):819-24
pubmed: 21507143
Langenbecks Arch Surg. 2009 Mar;394(2):221-6
pubmed: 19034493
Crit Care Med. 2011 Jul;39(7):1792-9
pubmed: 21358400
Crit Care. 2013 Dec 11;17(6):R291
pubmed: 24330744
Am J Respir Crit Care Med. 2014 Nov 15;190(10):1102-10
pubmed: 25295709
Crit Care. 2014 Mar 10;18(2):R44
pubmed: 24612487
Clin Infect Dis. 2004 Jul 15;39(2):206-17
pubmed: 15307030
JAMA. 2009 Sep 9;302(10):1059-66
pubmed: 19738090
JAMA Intern Med. 2016 Sep 1;176(9):1266-76
pubmed: 27428731
Ann Intensive Care. 2017 Nov 22;7(1):114
pubmed: 29168046
Chest. 2007 Jan;131(1):9-19
pubmed: 17218551